Results 271 to 280 of about 144,849 (341)

A 15‐year population‐based study on incidence and vaccination coverage in pediatric inflammatory bowel disease in Italy

Pediatric Investigation, EarlyView.
Increasing incidence of pediatric inflammatory bowel disease (IBD) and suboptimal vaccination coverage in Apulia, Italy (2009–2023). A total of 1044 incident cases of paediatric IBD were identified in the period 2009–2023 in Apulia, Italy, giving an average annual standardized incidence rate of 12.7/100 000. A significant increase in incidence occurred
Francesca Fortunato, Angelo Campanozzi, Michele Di Toma, Alessandra Marinari, Domenico Martinelli   +4 more
wiley   +1 more source

Association of appendectomy with disease phenotype and clinical course in Crohn's disease: results from two cohorts. [PDF]

Tech Coloproctol
Chen Y, Cheng Y, Song T, Zhang C, Peng H, Li Y.   +5 more
europepmc   +1 more source

The complications of Crohn's disease part one: The complications of acute and chronic intestinal disease

, 2014
Angela Galvin
openalex   +1 more source

Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound vesicles secreted by various cell types into the extracellular space and play a role in intercellular communication. Their molecular cargo varies depending on the cell of origin and its functional state.
Gloria Kemunto, Samaneh Ghadami, Kristen Dellinger   +2 more
wiley   +1 more source

Penoscrotal swelling as a presentation of Crohn's disease. [PDF]

J Surg Case Rep
Gandhi D, Tetarbe S, Sheth P, Shah I.
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Refractory Crohn's disease complicated with Guillain-Barré syndrome: A case report. [PDF]

World J Clin Cases
Liu AN, Yang JY, Chen XY, Wu SS, Ji Zhi SN, Zheng SM.   +5 more
europepmc   +1 more source

The Belgian Registry of Pediatric Crohn's disease (BELCRO) : growth status after 3 year follow up [PDF]

, 2014
Alliet, P, Bontems, P, De Greef, E, Hoffman, I, Mahanchie, J, Paquot, I, Smets, F, Van Biervliet, Stephanie, Van Steen, Kristel, Veereman-Wauters, G   +9 more
core  

Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Infliximab, a monoclonal antibody used for immune‐mediated diseases, shows high interpatient pharmacokinetic variability. Prolonged exposure increases the risk of adverse effects and costs, making dose personalization essential to balance safety, efficacy, and cost‐effectiveness. Population pharmacokinetic models support individualized dosing,
Sahira Chaiben, Peggy Gandia, Thibaut Jamme, Nicolas Congy, Didier Concordet   +4 more
wiley   +1 more source

Bibliometric analysis of Crohn's disease in children, 2014-2024. [PDF]

Front Pediatr
Zhu Y, Ma Y, Cui Z, Pan Y, Diao J.
europepmc   +1 more source